DISCOVER-ATTR
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease that remains largely under-recognized, under-diagnosed, and under-treated. It can be inherited or caused by abnormal deposition of wild-type transthyretin. New pharmacological therapies have shown promise in altering the disease trajectory and improving patient outcomes. However, there is a critical need for comprehensive data on patient characteristics and care patterns to enhance early diagnosis and treatment.
About the study
DISCOVER-ATTR Pilot Study is a single-center observational registry aimed at piloting the development of a decentralized, patient-powered digital registry for transthyretin amyloid cardiomyopathy (ATTR-CM). This study will capture multimodal patient data from electronic health records (EHRs) and wearable devices to evaluate the feasibility of remote patient enrollment and data collection.
-
You may qualify if you are attending a participating clinic at an enrolling site and:
Are over 18 years of age at the first visit.
Have a clinical diagnosis of ATTR amyloid cardiomyopathy
-
Participants will:
Electronically consent to join the study.
Share their EHR data through the Hugo Health platform.
Link their wearable device data to the registry via the CarDS Plus app.
-
Participants will receive a $50 prepaid electronic Visa gift card upon completing the data linkage process.
Learn More
Enrollment is limited to select health clinics at enrolling sites. If you have been contacted regarding enrollment in the study, please reach out to the relevant study team below.
Enrolling Sites
